04:21 AM EST, 11/10/2026 (MT Newswires) -- BioPharma Credit (BPCP.L, BPCR.L) and BioPharma Credit Investments V (Master) will invest up to $150 million in CorMedix under a two-tranche senior secured loan agreement, the British life sciences debt investment trust said Tuesday. BioPharma Credit's investment of up to $50 million, made through a subsidiary, will be used to support CorMedix's planned acquisition of substantially all of Heron Therapeutics' assets. The first tranche of $25 million will be available upon completion of the Heron acquisition, expected in the first quarter of 2027. The second tranche can be requested until June 30, 2028, to fund further acquisitions or in-licensing of commercial-stage pharmaceutical products. The loan, which matures five years after the first funding date, carries an interest rate of the three-month Secured Overnight Financing Rate, or SOFR, plus 5.75%, subject to a 3.50% SOFR floor. BioPharma Credit Investments V (Master) will invest up to $100 million in parallel for a total $150 million facility, and BioPharma Credit will act as collateral agent.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.